Targeting TROP‑2 in treatment‑resistant non‑small cell lung cancer harboring the KRAS G12C mutation and TROP‑2 upregulation: A case report

Oncology Letters 2026 Open access

Read full text
Authors: Lu Sun, Ying Xiong, Xiaobing Li, Yi Peng
DOI: 10.3892/ol.2026.15576
Cited by: 1
References: 57

Abstract

mutation are limited. Targeting TROP-2 may represent a novel therapeutic approach for patients with NSCLC, particularly those with chemo-radioresistant disease.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Protein Kinase Regulation and GTPase Signaling Protein Tyrosine Phosphatases

Publication details

Journal / source
Oncology Letters
Publisher
Spandidos Publications
Volume
31
Issue
6
Pages
1–9
Publication date
8 April 2026
Language
EN